This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (138)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Colon Cancer  • Gastrointestinal Diseases  • Alert me on articles by topic

Peter E. Valk, MB, BS; Elma Abella-Columna, MD; Michael K. Haseman, MD; Thomas R. Pounds, MD; Ruth D. Tesar; Richard W. Myers, MD; Hani B. Greiss, MD; Glenn A. Hofer, MD

Arch Surg. 1999;134:503-511.

Hypothesis  Metabolic imaging by positron emission tomography (PET) using [¹⁸F]fluorodeoxyglucose will be more accurate than anatomic imaging by computed tomography (CT) for detection of recurrent colorectal cancer. More accurate staging of recurrent tumor by PET will lead to more appropriate management decisions.

Design  Prospective blinded study comparing PET with CT, using histologic diagnosis, serial CT imaging, and clinical follow-up as criterion standards, with a fully blinded, retrospective reinterpretation of PET studies. Changes in diagnosis resulting from PET findings were correlated with subsequent treatment and surgical findings. Potential cost savings resulting from use of PET for preoperative staging were calculated.

Setting  Private practice in an outpatient tertiary referral center.

Patients  A group of 155 consecutive patients with imaging for diagnosis or staging of recurrent colorectal cancer. Twenty-one patient (14%) were excluded due to lack of a criterion standard. Computed tomographic scans were available for comparison for 115 patients.

Results  Positron emission tomographic scan sensitivity and specificity were 93% and 98%, respectively, compared with 69% and 96% for CT. Ninety-five percent confidence intervals for the differences between the modalities were 16% to 32% for sensitivity and 1% to 5% for specificity. The sensitivity of both modalities varied with anatomic site of recurrence. Positron emission tomographic scans were true positive in 12 (67%) of 18 patients with elevated serum carcinoembryonic antigen levels and negative CT findings. In 23 (29%) of 78 preoperative studies in which CT showed a single site of recurrence, PET showed tumor at additional sites. At surgery, nonresectable, PET-negative tumor was found in 7 (17%) of 42 patients who had PET evidence of localized recurrence only. Potential savings resulting from demonstration of nonresectable tumor by PET were calculated at $3003 per preoperative study.

Conclusions  Positron emission tomography was more sensitive and specific than CT for detection of recurrent colorectal cancer. Preoperative detection of nonresectable tumor by PET may avoid unnecessary surgery, and thereby reduce the cost of patient treatment.

From the Northern California PET Imaging Center (Drs Valk, Abella-Columna, Haseman, Pounds, Myers, Greiss, and Hofer and Ms Tesar); the Radiological Associates of Sacramento (Drs Valk, Haseman, Pounds, Myers, Greiss, and Hofer); and Sutter Cancer Center (Drs Greiss and Hofer), Sacramento, Calif. Peter E. Valk, MD, and Ruth D. Tesar are stockholders of PETNet Pharmaceutical Services LLC, Norcross, Ga.

RELATED ARTICLE

Invited Critique: Whole-Body PET Imaging With [¹⁸F]Fluorodeoxyglucose in Management of Recurrent Colorectal Cancer
Steven D. Wexner
Arch Surg. 1999;134(5):511-513.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

[18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial
de Wit et al.
Ann Oncol 2008;19:1619-1623.
ABSTRACT | FULL TEXT  

Preoperative Diagnosis of Lymph Node Metastases of Colorectal Cancer by FDG-PET/CT
Tsunoda et al.
Jpn J Clin Oncol 2008;38:347-353.
ABSTRACT | FULL TEXT  

The expanding role of PET technology in the management of patients with colorectal cancer
Herbertson et al.
Ann Oncol 2007;18:1774-1781.
ABSTRACT | FULL TEXT  

Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients?
Strobel et al.
Ann Oncol 2007;18:658-664.
ABSTRACT | FULL TEXT  

The Role of FDG-PET in the Selection of Patients with Colorectal Liver Metastases
Wiering et al.
Ann. Surg. Oncol. 2007;14:771-779.
ABSTRACT | FULL TEXT  

Comparison of Multiphase CT, FDG-PET and Intra-Operative Ultrasound in Patients with Colorectal Liver Metastases Selected for Surgery
Wiering et al.
Ann. Surg. Oncol. 2007;14:818-826.
ABSTRACT | FULL TEXT  

Early Detection of Cancer Recurrence: 18F-FDG PET/CT Can Make a Difference in Diagnosis and Patient Care
Israel and Kuten
JNM 2007;48:28S-35S.
ABSTRACT | FULL TEXT  

Diagnostic Accuracy of Colorectal Cancer Staging With Whole-Body PET/CT Colonography
Veit-Haibach et al.
JAMA 2006;296:2590-2600.
ABSTRACT | FULL TEXT  

Survival After Hepatic Resection for Colorectal Metastases: A 10-Year Experience
Wei et al.
Ann. Surg. Oncol. 2006;13:668-676.
ABSTRACT | FULL TEXT  

Positron-Emission Tomography and Assessment of Cancer Therapy
Juweid and Cheson
NEJM 2006;354:496-507.
FULL TEXT  

Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer
Veit et al.
Gut 2006;55:68-73.
ABSTRACT | FULL TEXT  

Use of a Decision Analysis Model to Assess the Cost-Effectiveness of 18F-FDG PET in the Management of Metachronous Liver Metastases of Colorectal Cancer
Lejeune et al.
JNM 2005;46:2020-2028.
ABSTRACT | FULL TEXT  

Colorectal Liver Metastases: CT, MR Imaging, and PET for Diagnosis--Meta-analysis
Bipat et al.
Radiology 2005;237:123-131.
ABSTRACT | FULL TEXT  

Fusion Image of Positron Emission Tomography and Computed Tomography for the Diagnosis of Local Recurrence of Rectal Cancer
Fukunaga et al.
Ann. Surg. Oncol. 2005;12:561-569.
ABSTRACT | FULL TEXT  

Comparison Between 18F-FDG PET, In-Line PET/CT, and Software Fusion for Restaging of Recurrent Colorectal Cancer
Kim et al.
JNM 2005;46:587-595.
ABSTRACT | FULL TEXT  

Is 18F-FDG PET/CT Useful for Imaging and Management of Patients with Suspected Occult Recurrence of Cancer?
Israel et al.
JNM 2004;45:2045-2051.
ABSTRACT | FULL TEXT  

Detection of Recurrence in Patients with Rectal Cancer: PET/CT after Abdominoperineal or Anterior Resection
Even-Sapir et al.
Radiology 2004;232:815-822.
ABSTRACT | FULL TEXT  

Malignant Involvement of the Spine: Assessment by 18F-FDG PET/CT
Metser et al.
JNM 2004;45:279-284.
ABSTRACT | FULL TEXT  

Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes
Jones et al.
Br. J. Radiol. 2004;77:74-75.
ABSTRACT | FULL TEXT  

In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography
Francis et al.
Gut 2003;52:1602-1606.
ABSTRACT | FULL TEXT  

PET/CT in Colorectal Cancer
Schiepers
JNM 2003;44:1804-1805.
FULL TEXT  

Positron Emission Tomography for Basal Cell Carcinoma of the Head and Neck
Fosko et al.
Arch Dermatol 2003;139:1141-1146.
ABSTRACT | FULL TEXT  

18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies
Chin and Wahl
Gut 2003;52:iv23-29.
ABSTRACT | FULL TEXT  

Clinical Role of FDG PET in Evaluation of Cancer Patients
Kostakoglu et al.
RadioGraphics 2003;23:315-340.
ABSTRACT | FULL TEXT  

Detection of Hepatic Metastases from Cancers of the Gastrointestinal Tract by Using Noninvasive Imaging Methods (US, CT, MR Imaging, PET): A Meta-Analysis
Kinkel et al.
Radiology 2002;224:748-756.
ABSTRACT | FULL TEXT  

Role of 18F-FDG Dual-Head Gamma-Camera Coincidence Imaging in Recurrent or Metastatic Colorectal Carcinoma
Even-Sapir et al.
JNM 2002;43:603-609.
ABSTRACT | FULL TEXT  

The Clinical Impact of 18F-FDG PET in Patients with Suspected or Confirmed Recurrence of Colorectal Cancer: A Prospective Study
Kalff et al.
JNM 2002;43:492-499.
ABSTRACT | FULL TEXT  

Clinical Applications of 18F-FDG in Oncology
Nabi and Zubeldia
J. Nucl. Med. Technol. 2002;30:3-9.
ABSTRACT | FULL TEXT  

In Vivo Imaging of Human Colon Cancer Xenografts in Immunodeficient Mice Using a Guanylyl Cyclase C-Specific Ligand
Wolfe et al.
JNM 2002;43:392-399.
ABSTRACT | FULL TEXT  

Selection of Patients for Resection of Hepatic Metastases: Improved Detection of Extrahepatic Disease with FDG PET
Zealley et al.
RadioGraphics 2001;21:S55-69.
ABSTRACT | FULL TEXT  

Whole body applications of positron emission tomography in oncology
Barrington
Imaging 2001;13:185-196.
ABSTRACT | FULL TEXT  

18F-FDG PET Detection of Colonic Adenomas
Yasuda et al.
JNM 2001;42:989-992.
ABSTRACT | FULL TEXT  

The clinical use of PET--where are we now?
Cook
Br. J. Radiol. 2001;74:399-401.
FULL TEXT  

A Tabulated Summary of the FDG PET Literature
Gambhir et al.
JNM 2001;42:1S-93.
FULL TEXT  

Impact of 18F-FDG PET on Managing Patients with Colorectal Cancer: The Referring Physician's Perspective
Meta et al.
JNM 2001;42:586-590.
ABSTRACT | FULL TEXT